With 2010 almost in the books—and a lot of people grounded by the Northeast blizzard—it seems like a good time to take a break and look back at some of Xconomy Boston’s top stories of the year.
These are not necessarily the ones that generated the most traffic (although in some cases they did). Instead, they are stories that best exemplify what we try to deliver to our readers day in and day out—the stories behind the companies, ideas, and people that are helping to create the future of innovation in our network of cities.
Our Boston editor’s picks span a wide range of subjects, from young startups (Baydin, Krush, Energesis) to established public companies (Genzyme, Vertex, Unica, Progress Software), from software and information technology to life sciences, biotech, and energy. They range from unique breaking news stories (Resveratrol) to in-depth features (TripAdvisor), Q&As (John Glaser, Arif Padaria), and commentary/analysis (entrepreneurial Walk of Fame).
Without further ado, here are our top 20 stories of 2010, sorted by sector:
Top 10 Tech Stories
Krush Founder Gina Ashe, Survivor of Horrific Car Crash, Has New Lease on Startup Life
Kendall Square Wants an Entrepreneurial Walk of Fame—and So Should Every Innovation Hub
The Unica Story: Yuchun Lee’s Journey from MIT Blackjack Team to IBM Acquisition
Is Boston Becoming a Hub for Female Tech Entrepreneurs? Maybe, and Here’s Why
Tim Berners-Lee and Group of Boston Web Gurus Leading New MIT Class to Get Linked Data to Market
Reinventing Progress Software—Boston’s Next Billion-Dollar Company?
TripAdvisor: The Travel Company That’s Really All About Data
.
Top 10 Life Sciences Stories
Avila Therapeutics Pursuing Rival to Lung Cancer Drug in Dana-Farber Lawsuit
Genzyme Boss Henri Termeer Not Ready to Sell to Sanofi, Ride Into the Sunset, Sources Say
Former Sirtris Execs’ Nonprofit Starts Selling Resveratrol with Potential Anti-Aging Effects Online
Vertex, Worth $7.5B, Eagerly Awaits Final Proof that Hepatitis C Drug Works
Cooking with the Genzyme Recipe: New Players Funding Rare Disease Drugs in Boston
The Genetics Institute Alumni: Where Are They Now?
Prominent Flatley Family Launches Boston Nonprofit for Cystic Fibrosis Drug Research
Chairman Bill Young: Next Biogen Idec CEO May Be a Scientist